News / FDA Approvals
Replimune RP1 BLA Resubmission Accepted by FDA; PDUFA Date Set for April 10, 2026
Replimune (NASDAQ: REPL) announced that the FDA has accepted the Biologics License Application (BLA) resubmission for RP1, in combination with nivolumab, for the treatment of advanced melanoma. The FDA has set a PDUFA target action date of...